Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

• DOI: 10.1038/s41467-022-31929-6
• Publication Date: 2022-07-27T14:02:42Z
• Authors: Li Wang; Markus H. Kainula...; Nannan Jiang; Han Di; Gaston Bonenfant; Lisa Mills; Michael Currier; Punya Shrivastava...; Brenda M. Calderon; Mili Sheth; Brian R. Mann; Jaber Hossain; Xudong Lin; Sandra Lester; Elizabeth A. Pusch; Joyce Jones; Dan Cui; Payel Chatterjee; M. Harley Jenks; Esther K. Morantz; Gloria P. Larson; Masato Hatta; Jennifer L. Harcourt; Azaibi Tamin; Yan Li; Ying Tao; Kun Zhao; Kristine Lacek; Ashley Burroughs; Wei Wang; Malania Wilson; Terianne Wong; So Hee Park; Suxiang Tong; John R. Barnes; Mark W. Tenforde; Wesley H. Self; Nathan I. Shapiro; Matthew C. Exline; D. Clark Files; Kevin W. Gibbs; David N. Hager; Manish Patel; Alison L. Halpin; Laura K. McMullan; Justin S. Lee; Hongjie Xia; Xuping Xie; Pei-Yong Shi; C. Todd Davis; Christina F. Spir...; Natalie J. Thornburg; M. Steven Oberste; Vivien G. Dugan; ; Dhwani Batra; Andrew S. Beck; Jason Caravas; Reina Chau; Roxana Cintron-Moret; Peter W. Cook; Jonathan Gerhart; Christopher A. Gu...; Norman Hassell; Dakota Howard; Kristen Knipe; Rebecca J. Kondor; Nicholas A. Kovacs; Kara Moser; Roopa Reddy-Nagilla; Clinton R. Paden; Benjamin Rambo-Ma...; Sandra Mathew; Matthew W. Schmerer; Samuel S. Shepard; Philip Shirk; Richard A. Stanton; Thomas J. Stark; Erisa Sula; Kendall Tymeckia; Yvette Unoarumhi; Voleti Subbalakshmi; Xiao-yu Zheng; David E. Wentworth; Bin Zhou
• Keywords: Vaccines, Synthetic; 0303 health sciences; COVID-19 Vaccines; SARS-CoV-2; Science; Q; COVID-19; Antibodies, Viral; Antibodies, Neutralizing; Article; 03 medical and health sciences; Neutralization Tests; Spike Glycoprotein, Coronavirus; Humans; mRNA Vaccines; Pandemics

AbstractThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.